KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) Interest Expenses (2017 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Interest Expenses for 16 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Interest Expenses rose 7.8% year-over-year to $2.8 million, compared with a TTM value of $10.9 million through Dec 2025, down 13.95%, and an annual FY2025 reading of $10.9 million, down 13.95% over the prior year.
  • Interest Expenses was $2.8 million for Q4 2025 at Biomarin Pharmaceutical, up from $2.6 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $6.1 million in Q4 2023 and bottomed at $2.6 million in Q4 2024.
  • Average Interest Expenses over 5 years is $3.6 million, with a median of $3.7 million recorded in 2023.
  • The sharpest move saw Interest Expenses tumbled 59.67% in 2021, then surged 68.17% in 2023.
  • Year by year, Interest Expenses stood at $3.8 million in 2021, then dropped by 5.72% to $3.6 million in 2022, then surged by 68.17% to $6.1 million in 2023, then crashed by 57.74% to $2.6 million in 2024, then increased by 7.8% to $2.8 million in 2025.
  • Business Quant data shows Interest Expenses for BMRN at $2.8 million in Q4 2025, $2.6 million in Q3 2025, and $2.7 million in Q2 2025.